Delving into the Latest Updates on Tianjin Genstar Biotech Co., Ltd. with Synapse

Overview

Basic Info

Introduction

Tianjin Genstar Biotech Co., Ltd. is situated in the economic heart of the Bohai Rim region, Tianjin, at No. 99 South Ring Road within the Tianjin Free Trade Zone (Airport Economic Area). The core expertise includes the R&D, production, and sales of bioproducts; the development, service, consultation, and transfer of biotechnology; international trade; as well as the import and export of goods and technologies, complemented by the sales of medical devices.

Tags

Other Diseases

Infectious Diseases

Prophylactic vaccine

Live attenuated vaccine

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

No Data

Disease Domain	Count

Infectious Diseases	1

Top 5 Drug Type	Count

Prophylactic vaccine	2
Live attenuated vaccine	1

研究冻干人用狂犬病疫苗（无血清Vero细胞）免疫原性和安全性。证明首剂接种后14天，实验组免前阴性人群的抗体阳转率和抗体几何均值（GMC）非劣效于对照组。全程免疫后14天，实验组免前阴性人群的抗体阳性率非劣效于对照组。评价受试人群以5剂免疫程序接种试验疫苗的安全性。

[Translation]

To study the immunogenicity and safety of freeze-dried human rabies vaccine (serum-free Vero cells). To prove that 14 days after the first dose, the antibody conversion rate and antibody geometric mean (GMC) of the pre-immunization negative population in the experimental group were non-inferior to those in the control group. 14 days after the full course of immunization, the antibody positivity rate of the pre-immunization negative population in the experimental group was non-inferior to that of the control group. To evaluate the safety of the experimental population inoculated with the test vaccine in a 5-dose immunization schedule.

Start Date-

Sponsor / Collaborator

Tianjin Genstar Biotech Co., Ltd.

CTR20221293

/ Active, not recruitingPhase 3

随机、盲法、阳性对照评价风疹减毒活疫苗（无血清MRC-5细胞）接种于18-50岁人群的免疫原性和安全性的Ⅲ期临床试验

[Translation] A randomized, blinded, positive-controlled phase III clinical trial to evaluate the immunogenicity and safety of live attenuated rubella vaccine (serum-free MRC-5 cells) in people aged 18-50 years

评价试验疫苗在18-50岁人群中接种的免疫原性和安全性

[Translation]

To evaluate the immunogenicity and safety of the experimental vaccine in people aged 18-50 years

Start Date10 Feb 2023

Sponsor / Collaborator

Tianjin Genstar Biotech Co., Ltd.

CTR20200069

/ CompletedPhase 1

开放、单臂、单中心评价风疹减毒活疫苗（无血清MRC-5细胞）接种于18周岁及以上人群的安全性的I期临床试验

[Translation] An open, single-arm, single-center phase I clinical trial to evaluate the safety of live attenuated rubella vaccine (serum-free MRC-5 cells) in people aged 18 years and above

评价风疹减毒活疫苗（无血清MRC-5细胞）接种于18周岁及以上人群的安全性。

[Translation]

To evaluate the safety of live attenuated Rubella vaccine (serum-free MRC-5 cells) in people aged 18 years and above.

Start Date17 Jan 2020

Sponsor / Collaborator

Tianjin Genstar Biotech Co., Ltd.

100 Clinical Results associated with Tianjin Genstar Biotech Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Tianjin Genstar Biotech Co., Ltd.

Login to view more data

100 Deals associated with Tianjin Genstar Biotech Co., Ltd.

Login to view more data

100 Translational Medicine associated with Tianjin Genstar Biotech Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 11 Jun 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 3 Clinical

2

Login to view more data